Die folgenden Empfehlungen sind als Unterstützung und Anregung gedacht, die stets individüll angepasst und abgewandelt werden können. Sie basieren auf unserem Wissensstand vom23.03.2020-
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna
Stand 21. Dezember 2021
(Первинна та бустерна вакцинації) – з векторною вакциною – (вакцина Janssen® від COVID-19 виробництва Janssen Cilag International/Johnson & Johnson
Станом на: 14 лютого 2022 р. (даний інформаційн...й лист постійно оновлюється)
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019)
(Grundimmunisierung und Auffrischimpfungen) – mit Vektor-Impfstoff – (COVID-19 Vaccine Janssen® von Janssen Cilag International/Johnson & Johnson)
Stand: 14. Februar 2022 (dieses Aufklärungsmerkblatt wird laufend aktualisiert)
more
L’OMS recommande aux femmes enceintes de faire un test de dépistage du VIH, de la syphilis et de l’hépatite B (HBsAg) au moins une fois pendant la grossesse, de préférence au cours du premier trimestre. Le double test de diagnostic rapide (TDR) VIH/syphilis peut être utilisé comme premier ...test pour les femmes enceintes dans le cadre des soins prénataux. Ces tests simples peuvent être utilisés sur le lieu de soins et sont économiques par rapport aux tests standards de soins prénataux.
more
2018
9th Edition
Offering information on HIV/AIDS treatment, prevention, and research
– (Comirnaty® 10 мкг або 30 мкг виробництва BioNTech/Pfizer та
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Corona Virus Disease 2019) (Grundimmunisierung und Auffrischimpfungen)
– mit mRNA-Impfstoffen –
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer... und Spikevax® von Moderna)
more
– з вакциною на білковій основі
(Nuvaxovid® виробництва Novavax)
Станом на: 15 лютого 2022 р. (даний інформаційний лист постійно оновлюється)
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Cor...ona Virus Disease 2019) (Grundimmunisierung )
– mit proteinbasiertem Impfstoff –
(Nuvaxovid® von Novavax)
Stand: 15. Februar 2022 (dieser Aufklärungsbogen wird laufend aktualisiert)
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer und Spikevax® von Moderna)
more
Epidemiologische Lage
Grundsätze für die Hausärztliche Praxis
Organisatorische Hinweise
Mögliche Optionen zur Entlastung der Praxis
Klinische Hinweise zur Behandlung von Covid-19-Fällen
Weitere Informationen
The Global Action Plan on Antimicrobial Resistance (AMR) calls for making AMR a core component of professional education and training. In 2018, the World Health Organization (WHO) published Competency framework for health workers’ education and training on AMR to ensure that academic institutions ...and regulatory agencies provided pre-service and in-service training to equip health workers with the adequate competencies to address AMR. This was followed by Health workers’ training and education on AMR: curricula guide, which outlines the learning objectives and expected outcomes of pre-service training of health workers to improve curricula. These tools were designed to strengthen the capacity of health workers in various settings to address the growing challenge of AMR.
more
Hand hygiene is vital for safe health care delivery, yet practices at the point of care remain suboptimal worldwide. A comprehensive research agenda is therefore necessary to improve our understanding of factors influencing hand hygiene behaviour and to strengthen appropriate interventions. This age...nda will provide insightful ideas for researchers to focus their projects and funding proposals and will direct donors towards the areas of hand hygiene evidence that require urgent support and innovation. It will also guide decision-makers and stakeholders at the national and international level and support country efforts in updating and strengthening hand hygiene promotion programmes. Global collaboration and investment in hand hygiene research remain essential to promote safe and effective care worldwide.
more
The UNAIDS 2020 global report is a call to action. It highlights the scale of the HIV epidemic and how it runs along the fault lines of inequalities.
PLoS Negl Trop Dis 13(10): e0007694. In 2005, the World Health Organization (WHO) recognized Chagas disease (CD; Trypanosoma cruzi infection) as a neglected tropical disease (NTD) [1] and included it into the global plan to combat NTDs [2]. The Target 3.3 of the United Nations Sustainable Developmen...t Goals (UN/SDG) aims at ending the epidemics of NTDs by 2030 [3]. Mother-to-child (congenital/connatal) transmission is currently the main mode of transmission of T. cruzi over blood transfusions and organ transplantations in vector-free areas within and outside Latin America (LA). Based on recent demonstrations that congenital transmission can be prevented [4–7], WHO has shifted its objective, in 2018, from control to elimination of congenital CD (cCD).
more
No publication year indicated
The specific objectives of the plan are to:
- Scale up evidence-based, cost effective interventions through effective strategies within a HSS approach and provide equitable coverage with quality.
- Reduce neonatal mortality by improved home-based newborn ...care, early identification of sick newborns and improved access to institutional newborn care of adequate quality.
- Reduce common childhood illness related mortality (due to pneumonia and diarrhoea in all areas and malaria in endemic areas) by improving key family and community practices, community-based early diagnosis and management and referral care for complicated cases.
more
Government of Nepal has an obligation to ensure availability of affordable and high quality basic health care services to its population
Dengue is a mosquito-borne viral disease that occurs mainly in the tropics and subtropics but has a high potential to spread to new areas. Dengue infections are climate sensitive, so it is important to better understand how changing climate factors affect the potential for geographic spread and futu...re dengue epidemics. Vectorial capacity (VC) describes a vector's propensity to transmit dengue taking into account human, virus, and vector interactions. VC is highly temperature dependent, but most dengue models only take mean temperature values into account. Recent evidence shows that diurnal temperature range (DTR) plays an important role in influencing the behavior of the primary dengue vector Aedes aegypti. In this study, we used relative VC to estimate dengue epidemic potential (DEP) based on the temperature and DTR dependence of the parameters of A. aegypti. We found a strong temperature dependence of DEP; it peaked at a mean temperature of 29.3°C when DTR was 0°C and at 20°C when DTR was 20°C. Increasing average temperatures up to 29°C led to an increased DEP, but temperatures above 29°C reduced DEP. In tropical areas where the mean temperatures are close to 29°C, a small DTR increased DEP while a large DTR reduced it. In cold to temperate or extremely hot climates where the mean temperatures are far from 29°C, increasing DTR was associated with increasing DEP. Incorporating these findings using historical and predicted temperature and DTR over a two hundred year period (1901-2099), we found an increasing trend of global DEP in temperate regions. Small increases in DEP were observed over the last 100 years and large increases are expected by the end of this century in temperate Northern Hemisphere regions using climate change projections. These findings illustrate the importance of including DTR when mapping DEP based on VC.
more
Hendra virus (HeV) continues to pose a serious public health concern as spillover events occur sporadically. Terminally ill horses can exhibit a range of clinical signs including frothy nasal discharge, ataxia or forebrain signs. Early signs, if detected, can include depression, inappetence, colic o...r mild respiratory signs. All unvaccinated ill horses in areas where flying foxes exist, may potentially be infected with HeV, posing a significant risk to the veterinary community. Equivac® HeV vaccine has been fully registered in Australia since 2015 (and under an Australian Pesticides and Veterinary Medicines Authority special permit since 2012) for immunization of horses against HeV and is the most effective and direct solution to prevent disease transmission to horses and protect humans. No HeV vaccinated horse has tested positive for HeV infection. There is no registered vaccine to prevent, or therapeutics to treat, HeV infection in humans. Previous equine HeV outbreaks tended to cluster in winter overlapping with the foaling season (August to December), when veterinarians and horse owners have frequent close contact with horses and their bodily fluids, increasing the chance of zoonotic disease transmission. The most southerly case was detected in 2019 in the Upper Hunter region in New South Wales, which is Australia's Thoroughbred horse breeding capital. Future spillover events are predicted to move further south and inland in Queensland and New South Wales, aligning with the moving distribution of the main reservoir hosts. Here we (1) review HeV epidemiology and climate change predicted infection dynamics, (2) present a biosecurity protocol for veterinary clinics and hospitals to adopt, and (3) describe diagnostic tests currently available and those under development. Major knowledge and research gaps have been identified, including evaluation of vaccine efficacy in foals to assess current vaccination protocol recommendations.
more